The approval of Takeda Pharmaceuticals U.S.A.'s and Orexigen Therapeutics Inc.'s Contrave (naltrexone and bupropion) in September and Saxenda (liraglutide) from Novo Nordisk A/S last month doubled the number of obesity drugs approved by the FDA in the last two and a half years.